{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:35:16Z","timestamp":1786980916034,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:00:00Z","timestamp":1697241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the China International Medical Foundation Project","award":["Z-2014-06-2103"],"award-info":[{"award-number":["Z-2014-06-2103"]}]},{"name":"the Project of Jiangsu Cancer Hospital","award":["ZJ202110"],"award-info":[{"award-number":["ZJ202110"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82272863"],"award-info":[{"award-number":["82272863"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Medical and Health Foundation Project","award":["YWJKJJHKYJJ-F2030E"],"award-info":[{"award-number":["YWJKJJHKYJJ-F2030E"]}]},{"name":"the Huilan Public Interest Project","award":["HL-HS-2020102"],"award-info":[{"award-number":["HL-HS-2020102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Anlotinib plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC) achieves good efficacy, but there is still room for improvement. This clinical study examined the effectiveness of anlotinib plus etoposide for maintenance therapy in ES-SCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The current single-arm, prospective phase II study was performed at Jiangsu Cancer Hospital (March 2019 to March 2022). After successful primary etoposide-based therapy, anlotinib was administered at 12\u00a0mg\/day on days 1 to 14 of 21-day cycles until disease progression or consent withdrawal. All patients also received etoposide at 50\u00a0mg\/day on days 1 to 14 of 21-day cycles for a maximum of six cycles. Progression-free survival (PFS) constituted the primary study endpoint. Secondary endpoints were overall survival (OS), objective remission rate (ORR), disease control rate (DCR), and safety. In addition, adverse events (AEs) were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-eight patients were treated. Median PFS and OS were 8.02 (95%CI 5.36\u201310.67) and 11.04 (95%CI 10.37\u201311.68) months, respectively. Totally 9 and 18 participants showed a partial response and stable disease, respectively; ORR and DCR were 32.14% and 96.43%, respectively. The commonest all-grade AEs were fatigue (n\u2009=\u200911, 39.28%), hypertension (n\u2009=\u200911, 39.28%), loss of appetite (n\u2009=\u20099, 32.14%), oral mucositis (n\u2009=\u20097, 25.00%) and proteinuria (n\u2009=\u20096, 21.40%). Grade 3\u20134 AEs included fatigue (n\u2009=\u20094, 14.28%), hypertension (n\u2009=\u20092, 7.14%), hand and foot syndrome (n\u2009=\u20092, 7.14%), oral mucositis (n\u2009=\u20091, 3.57%), hemoptysis (n\u2009=\u20091, 3.57%), proteinuria (n\u2009=\u20091, 3.57%), gingival bleeding (n\u2009=\u20091, 3.57%), and serum creatinine elevation (n\u2009=\u20091, 3.57%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Maintenance anlotinib plus etoposide achieves promising PFS and OS in clinical ES-SCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Registration number<\/jats:title>\n                    <jats:p>ChiCTR1800019421.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10637-023-01398-9","type":"journal-article","created":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T02:01:37Z","timestamp":1697248897000},"page":"825-833","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial"],"prefix":"10.1007","volume":"41","author":[{"given":"Yuan","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengxiang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhu","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banzhou","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renhong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoren","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jifeng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,14]]},"reference":[{"key":"1398_CR1","volume-title":"Small cell Lung Cancer. Version 2.2023","author":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)","year":"2022","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) (2022) Small cell Lung Cancer. Version 2.2023. National Comprehensive Cancer Network, Fort Washington"},{"key":"1398_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C et al (2021) Small-cell lung cancer. Nat Rev Dis Primers 7:3. https:\/\/doi.org\/10.1038\/s41572-020-00235-0","journal-title":"Nat Rev Dis Primers"},{"key":"1398_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"1398_CR4","doi-asserted-by":"publisher","first-page":"e142S","DOI":"10.1378\/chest.12-2353","volume":"143","author":"MP Rivera","year":"2013","unstructured":"Rivera MP, Mehta AC, Wahidi MM (2013) Establishing the diagnosis of lung cancer: diagnosis and management of lung cancer, 3rd ed: american college of chest Physicians evidence-based clinical practice guidelines. Chest 143:e142S\u2013e165S. https:\/\/doi.org\/10.1378\/chest.12-2353","journal-title":"Chest"},{"key":"1398_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics, 2022. CA Cancer J Clin 72:7\u201333. https:\/\/doi.org\/10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"key":"1398_CR6","doi-asserted-by":"publisher","first-page":"e73805","DOI":"10.1371\/journal.pone.0073805","volume":"8","author":"H Zhou","year":"2013","unstructured":"Zhou H, Zeng C, Wei Y et al (2013) Duration of chemotherapy for small cell lung cancer: a meta-analysis. PLoS ONE 8:e73805. https:\/\/doi.org\/10.1371\/journal.pone.0073805","journal-title":"PLoS ONE"},{"key":"1398_CR7","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS et al (2021) Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung Cancer treated with atezolizumab, carboplatin, and Etoposide (IMpower133). J Clin Oncol 39:619\u2013630. https:\/\/doi.org\/10.1200\/JCO.20.01055","journal-title":"J Clin Oncol"},{"key":"1398_CR8","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394:1929\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6","journal-title":"Lancet"},{"key":"1398_CR9","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szczesna A et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell Lung Cancer. N Engl J Med 379:2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"key":"1398_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","volume":"22","author":"JW Goldman","year":"2021","unstructured":"Goldman JW, Dvorkin M, Chen Y et al (2021) Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22:51\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30539-8","journal-title":"Lancet Oncol"},{"key":"1398_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.lungcan.2004.03.006","volume":"46","author":"S Tanno","year":"2004","unstructured":"Tanno S, Ohsaki Y, Nakanishi K et al (2004) Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3. Lung Cancer 46:11\u201319. https:\/\/doi.org\/10.1016\/j.lungcan.2004.03.006","journal-title":"Lung Cancer"},{"key":"1398_CR12","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1200\/JCO.2016.69.4844","volume":"35","author":"M Tiseo","year":"2017","unstructured":"Tiseo M, Boni L, Ambrosio F et al (2017) Italian, Multicenter, Phase III, Randomized Study of Cisplatin Plus Etoposide with or without Bevacizumab as First-Line treatment in extensive-disease small-cell Lung Cancer: the GOIRC-AIFA FARM6PMFJM Trial. J Clin Oncol 35:1281\u20131287. https:\/\/doi.org\/10.1200\/JCO.2016.69.4844","journal-title":"J Clin Oncol"},{"key":"1398_CR13","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/annonc\/mdv065","volume":"26","author":"JL Pujol","year":"2015","unstructured":"Pujol JL, Lavole A, Quoix E et al (2015) Randomized phase II-III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trialdagger. Ann Oncol 26:908\u2013914. https:\/\/doi.org\/10.1093\/annonc\/mdv065","journal-title":"Ann Oncol"},{"key":"1398_CR14","doi-asserted-by":"publisher","first-page":"655316","DOI":"10.3389\/fonc.2021.655316","volume":"11","author":"A Montanino","year":"2021","unstructured":"Montanino A, Manzo A, Carillio G et al (2021) Angiogenesis inhibitors in small cell Lung Cancer. Front Oncol 11:655316. https:\/\/doi.org\/10.3389\/fonc.2021.655316","journal-title":"Front Oncol"},{"key":"1398_CR15","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13045-018-0664-7","volume":"11","author":"G Shen","year":"2018","unstructured":"Shen G, Zheng F, Ren D et al (2018) Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol 11:120. https:\/\/doi.org\/10.1186\/s13045-018-0664-7","journal-title":"J Hematol Oncol"},{"key":"1398_CR16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41419-020-2511-3","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu S, Qin T, Liu Z et al (2020) Anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells. Cell Death Dis 11:309. https:\/\/doi.org\/10.1038\/s41419-020-2511-3","journal-title":"Cell Death Dis"},{"key":"1398_CR17","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00262-020-02641-5","volume":"69","author":"Y Yang","year":"2020","unstructured":"Yang Y, Li L, Jiang Z et al (2020) Anlotinib optimizes anti-tumor innate immunity to potentiate the therapeutic effect of PD-1 blockade in lung cancer. Cancer Immunol Immunother 69:2523\u20132532. https:\/\/doi.org\/10.1007\/s00262-020-02641-5","journal-title":"Cancer Immunol Immunother"},{"key":"1398_CR18","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/1759-7714.14414","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, Liao J, Wu X et al (2022) A phase II study of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer. Thorac Cancer 13:1463\u20131470. https:\/\/doi.org\/10.1111\/1759-7714.14414","journal-title":"Thorac Cancer"},{"key":"1398_CR19","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s10637-022-01279-7","volume":"40","author":"T Kong","year":"2022","unstructured":"Kong T, Chen L, Zhao X et al (2022) Anlotinib plus etoposide and cisplatin\/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study. Invest New Drugs 40:1095\u20131105. https:\/\/doi.org\/10.1007\/s10637-022-01279-7","journal-title":"Invest New Drugs"},{"key":"1398_CR20","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1002\/cam4.4736","volume":"11","author":"P Deng","year":"2022","unstructured":"Deng P, Hu C, Chen C et al (2022) Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: a single-arm trial. Cancer Med 11:3563\u20133571. https:\/\/doi.org\/10.1002\/cam4.4736","journal-title":"Cancer Med"},{"key":"1398_CR21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cllc.2016.05.008","volume":"17","author":"G Roviello","year":"2016","unstructured":"Roviello G, Zanotti L, Cappelletti MR et al (2016) No advantage in Survival with targeted therapies as maintenance in patients with Limited and extensive-stage small cell Lung Cancer: A literature-based Meta-analysis of Randomized trials. Clin Lung Cancer 17:334\u2013340. https:\/\/doi.org\/10.1016\/j.cllc.2016.05.008","journal-title":"Clin Lung Cancer"},{"key":"1398_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/1759-7714.12019","volume":"4","author":"L Li","year":"2013","unstructured":"Li L, Li Q, Xu Y et al (2013) Phase II study of oral etoposide maintenance for patients with extensive stage small cell lung cancer who have responded to the induction on an EP regimen. Thorac Cancer 4:234\u2013240. https:\/\/doi.org\/10.1111\/1759-7714.12019","journal-title":"Thorac Cancer"},{"key":"1398_CR23","doi-asserted-by":"publisher","first-page":"343","DOI":"10.21037\/jtd-21-106","volume":"13","author":"C Zhang","year":"2021","unstructured":"Zhang C, Duan J, He Z et al (2021) The benefits of etoposide capsules as maintenance therapy for patients with extensive-stage small cell lung cancer: a prospective two-stage, two-center study. J Thorac Dis 13:343\u2013352. https:\/\/doi.org\/10.21037\/jtd-21-106","journal-title":"J Thorac Dis"},{"key":"1398_CR24","doi-asserted-by":"publisher","first-page":"e229","DOI":"10.1016\/j.cllc.2015.05.005","volume":"16","author":"R Petrioli","year":"2015","unstructured":"Petrioli R, Roviello G, Laera L et al (2015) Cisplatin, Etoposide, and Bevacizumab Regimen followed by oral etoposide and bevacizumab maintenance treatment in patients with extensive-stage small cell Lung Cancer: a Single-Institution experience. Clin Lung Cancer 16:e229\u2013234. https:\/\/doi.org\/10.1016\/j.cllc.2015.05.005","journal-title":"Clin Lung Cancer"},{"key":"1398_CR25","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1200\/JCO.2010.29.3423","volume":"29","author":"DR Spigel","year":"2011","unstructured":"Spigel DR, Townley PM, Waterhouse DM et al (2011) Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 29:2215\u20132222. https:\/\/doi.org\/10.1200\/JCO.2010.29.3423","journal-title":"J Clin Oncol"},{"key":"1398_CR26","doi-asserted-by":"publisher","first-page":"6006","DOI":"10.1200\/JCO.2009.23.7545","volume":"27","author":"L Horn","year":"2009","unstructured":"Horn L, Dahlberg SE, Sandler AB et al (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 27:6006\u20136011. https:\/\/doi.org\/10.1200\/JCO.2009.23.7545","journal-title":"J Clin Oncol"},{"key":"1398_CR27","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1097\/JTO.0b013e3181f0bd78","volume":"5","author":"BJ Gitlitz","year":"2010","unstructured":"Gitlitz BJ, Moon J, Glisson BS et al (2010) Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial. J Thorac Oncol 5:1835\u20131840. https:\/\/doi.org\/10.1097\/JTO.0b013e3181f0bd78","journal-title":"J Thorac Oncol"},{"key":"1398_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3978\/j.issn.2218-6751.2015.06.03","volume":"4","author":"BJ Schneider","year":"2015","unstructured":"Schneider BJ (2015) Maintenance sunitinib for extensive-stage small cell lung cancer: a new standard, an option or a step in the right direction? Transl Lung Cancer Res 4:635\u2013638. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2015.06.03","journal-title":"Transl Lung Cancer Res"},{"key":"1398_CR29","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/bjc.2017.465","volume":"118","author":"JM Sun","year":"2018","unstructured":"Sun JM, Lee KH, Kim BS et al (2018) Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled phase II study (KCSG-LU12-07). Br J Cancer 118:648\u2013653. https:\/\/doi.org\/10.1038\/bjc.2017.465","journal-title":"Br J Cancer"},{"key":"1398_CR30","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s10637-019-00828-x","volume":"38","author":"H Luo","year":"2020","unstructured":"Luo H, Zhang L, Yang B et al (2020) A randomized phase 2 trial of apatinib vs observation as maintenance treatment following first-line induction chemotherapy in extensive- stage small cell lung cancer. Invest New Drugs 38:148\u2013159. https:\/\/doi.org\/10.1007\/s10637-019-00828-x","journal-title":"Invest New Drugs"},{"key":"1398_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/1759-7714.14298","volume":"13","author":"F Teng","year":"2022","unstructured":"Teng F, Xing P, Yang K et al (2022) Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: a phase II single-arm trial. Thorac Cancer 13:557\u2013562. https:\/\/doi.org\/10.1111\/1759-7714.14298","journal-title":"Thorac Cancer"},{"key":"1398_CR32","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/cam4.4507","volume":"11","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Wang Q, Li K et al (2022) Anlotinib for patients with small cell lung cancer and baseline liver metastases: a post hoc analysis of the ALTER 1202 trial. Cancer Med 11:1081\u20131087. https:\/\/doi.org\/10.1002\/cam4.4507","journal-title":"Cancer Med"},{"key":"1398_CR33","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.21037\/tlcr-21-632","volume":"10","author":"Y Liu","year":"2021","unstructured":"Liu Y, Cheng Y, Li K et al (2021) Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial. Transl Lung Cancer Res 10:3793\u20133806. https:\/\/doi.org\/10.21037\/tlcr-21-632","journal-title":"Transl Lung Cancer Res"},{"key":"1398_CR34","doi-asserted-by":"publisher","first-page":"917089","DOI":"10.3389\/fonc.2022.917089","volume":"12","author":"J Yuan","year":"2022","unstructured":"Yuan J, Cheng F, Xiao G et al (2022) Efficacy and safety of Anlotinib in the treatment of small cell Lung Cancer: A Real-World Observation Study. Front Oncol 12:917089. https:\/\/doi.org\/10.3389\/fonc.2022.917089","journal-title":"Front Oncol"},{"key":"1398_CR35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/CAD.0000000000001488","volume":"34","author":"N Wang","year":"2023","unstructured":"Wang N, Zhao L, Zhang D et al (2023) Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer. Anticancer Drugs 34:558\u2013562. https:\/\/doi.org\/10.1097\/CAD.0000000000001488","journal-title":"Anticancer Drugs"},{"key":"1398_CR36","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1002\/ijc.33161","volume":"147","author":"D Wu","year":"2020","unstructured":"Wu D, Nie J, Hu W et al (2020) A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. Int J Cancer 147:3453\u20133460. https:\/\/doi.org\/10.1002\/ijc.33161","journal-title":"Int J Cancer"},{"key":"1398_CR37","doi-asserted-by":"publisher","first-page":"11133","DOI":"10.2147\/CMAR.S275624","volume":"12","author":"PF Song","year":"2020","unstructured":"Song PF, Xu N, Li Q (2020) Efficacy and safety of Anlotinib for Elderly patients with previously treated extensive-stage SCLC and the Prognostic significance of common adverse reactions. Cancer Manag Res 12:11133\u201311143. https:\/\/doi.org\/10.2147\/CMAR.S275624","journal-title":"Cancer Manag Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01398-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01398-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01398-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:07:25Z","timestamp":1700597245000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01398-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,14]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01398-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,14]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This trial complied with the Declaration of Helsinki (2000) of the World Medical Association. It had approval from the Ethics Committee of the Jiangsu Cancer Hospital. Signed informed consent was provided by each patient. The study was registered at the Chinese clinical trial registry (\n                      \n                      , ChiCTR1800019421).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Signed informed consent was provided by each patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"N\/A.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal Studies"}}]}}